AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B

AbbVie is setting up a shot to buy Kestrel Therapeutics down the line, as the biotech doses patients in a Phase 1 trial for the oral pan-KRAS inhibitor KST-6051 in solid tumors.